Pfizer Q2 Earnings Preview--Should You Buy, Hold, or Sell?
Aug 5 - Pfizer 
PFE released its Q2 earnings amid growing investor caution. Pfizer's revenue rose 10% to $14.7 billion, beating Wall Street expectations and signaling a potential rebound in its core business after the post-COVID slump.
The company underperformed last quarter, missing revenue targets by about 1.6% with $13.72 billion in sales and organic top-line growth showing softness.
Sector rivals, Bristol?Myers Squibb and Merck, reported mixed results, signaling broader industry challenges. Meanwhile, Pfizer faces looming patent expiries on blockbuster drugs such as Eliquis, Ibrance, and Xtandi in 20262027. The collapse in COVID?19 vaccine and Paxlovid sales remains a drag, COVID revenue dropped by over 75% from 2022 to 2024.
Pfizer maintained its 2025 forecast of $61 vs. $64billion in sales and 2.80-3.00 EPS. Through automation and artificial intelligence, the management is planning to cut costs by $1.2 billion this year, peaking at an additional almost 7.7 billion by 2027. Investors will be keen to hear a response to the issue of rising regulatory and political pressure on prices by CEO Albert Bourla.
Is PFE Stock a Buy or Sell?
Based on the one year price targets offered by 21 analysts, the average target price for Pfizer Inc is $28.76 with a high estimate of $41.49 and a low estimate of $23.00. The average target implies a upside of +22.23% from the current price of $23.53.
Based on GuruFocus estimates, the estimated GF Value for Pfizer Inc in one year is $27.26, suggesting a upside of +15.85% from the current price of $23.53. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page.